Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart

Title: Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart
Authors: Sebastian Korste; Stephan Settelmeier; Lars Michel; Andrea Odersky; Pia Stock; Fabrice Reyes; Elias Haj-Yehia; Markus S. Anker; Anika Grüneboom; Ulrike B. Hendgen-Cotta; Tienush Rassaf; Matthias Totzeck
Source: International Journal of Molecular Sciences, Vol 24, Iss 7, p 6052 (2023)
Publisher Information: MDPI AG
Publication Year: 2023
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: cardio-oncology; cardiotoxicity; doxorubicin; immune checkpoint inhibitor; programmed cell death ligand 1; Biology (General); QH301-705.5; Chemistry; QD1-999
Description: Cancer survival rates have increased significantly because of improvements in therapy regimes and novel immunomodulatory drugs. Recently, combination therapies of anthracyclines and immune checkpoint inhibitors (ICIs) have been proposed to maximize neoplastic cell removal. However, it has been speculated that a priori anthracycline exposure may prone the heart vulnerable to increased toxicity from subsequent ICI therapy, such as an anti-programmed cell death protein 1 (PD1) inhibitor. Here, we used a high-dose anthracycline mouse model to characterize the role of the PD1 immune checkpoint signaling pathway in cardiac tissue using flow cytometry and immunostaining. Anthracycline treatment led to decreased heart function, increased concentration of markers of cell death after six days and a change in heart cell population composition with fewer cardiomyocytes. At the same time point, the number of PD1 ligand (PDL1)-positive immune cells and endothelial cells in the heart decreased significantly. The results suggest that PD1/PDL1 signaling is affected after anthracycline treatment, which may contribute to an increased susceptibility to immune-related adverse events of subsequent anti-PD1/PDL1 cancer therapy.
Document Type: article in journal/newspaper
Language: English
Relation: https://www.mdpi.com/1422-0067/24/7/6052; https://doaj.org/toc/1661-6596; https://doaj.org/toc/1422-0067; https://doaj.org/article/663aacb6082341939843d1d2a1a8eedb
DOI: 10.3390/ijms24076052
Availability: https://doi.org/10.3390/ijms24076052; https://doaj.org/article/663aacb6082341939843d1d2a1a8eedb
Accession Number: edsbas.27EA74F
Database: BASE